Chapter review

Fitzgerald PMHNP board review. ch09. Anxiety Disorders. This is drive 2 of 7. When I say Pause. Answer. wait, then I will give the answer. New section. Anxiety disorders: criteria, timelines, and look-alikes. Topic. Generalized Anxiety Disorder (GAD) Criteria. Bottom Line Summary. * Diagnostic criteria require excessive anxiety and worry occurring on most days for at least 6 months regarding multiple events or activities source 1. * Adults must demonstrate at least 3 of the 6 **WATCHERS** somatic and cognitive symptoms, whereas children require only 1 symptom [1, 2]. * The **WATCHERS** mnemonic stands for **Worry**, **Anxiety**, **Tension** in muscles, **Concentration** problems, **Hyperarousal** or irritability, **Energy** loss or fatigue, **Restlessness**, and **Sleep** disturbance [2-4]. * Objective severity is assessed using the **GAD-7** scale, where scores of 5 to 9 indicate mild anxiety, 10 to 14 indicate moderate anxiety, and 15 to 21 indicate severe anxiety source 5. * **First-line** pharmacotherapy includes **SSRIs** such as **sertraline** or **SNRIs** such as **duloxetine**, along with **buspirone**, which carries a direct FDA indication for **generalized anxiety disorder** [6, 7]. * **Safety alert.** Always rule out medical mimics such as hyperthyroidism and substance-induced anxiety before establishing a primary psychiatric diagnosis [8-10]. * **Board trap.** Up to 75 percent of patients present in primary care with somatic complaints rather than explicit worry, and 50 to 90 percent have a comorbid psychiatric disorder such as **major depressive disorder** [11, 12]. * Maintenance treatment lasts 6 to 12 months, but abrupt discontinuation leads to a 25 percent relapse rate within 1 month and a 60 to 80 percent relapse rate within 1 year [13, 14]. High-Yield Clinical Teaching: Generalized Anxiety Disorder Criteria. Diagnostic Criteria and DSM-5-TR Timelines. **Generalized anxiety disorder** is defined by persistent, excessive, and uncontrollable anxiety and worry occurring on most days for a minimum of 6 months [1, 10]. The worry is pervasive and involves multiple life domains such as work, health, finances, and family source 1. To meet full criteria, the clinical picture must cause significant distress or functional impairment in social, occupational, or other important areas of functioning source 10. The **WATCHERS** mnemonic helps clinicians recall the required associated symptoms [2-4]: * **W**: **Worry** or apprehensive expectation that is difficult to control [2, 3]. * **A**: **Anxiety** that is excessive and out of proportion to real threats [2, 3]. * **T**: **Tension** in muscles or physical stiffness [2, 4]. * **C**: **Concentration** difficulty or the mind going blank [2, 4]. * **H**: **Hyperarousal** or irritability [2, 4]. * **E**: **Energy** loss or fatigue [2, 4]. * **R**: **Restlessness** or feeling keyed up or on edge [2, 4]. * **S**: **Sleep** disturbance, most commonly difficulty initiating sleep [2, 4]. Adults must meet at least 3 of these associated symptoms occurring on most days over the 6 month duration source 1. In pediatric patients, only 1 symptom is necessary, and excessive worry in children frequently centers on personal competence or academic performance [1, 2]. Rating Scales and Assessment Tools. The **GAD-7** is the primary standardized self-report tool used to screen and quantify severity [5, 15]. Scores are categorized cleanly into three tiers source 5: * Scores of 5 to 9 reflect mild anxiety source 5. * Scores of 10 to 14 reflect moderate anxiety source 5. * Scores of 15 to 21 reflect severe anxiety source 5. In clinical practice, a **GAD-7** score of 10 or greater serves as a typical threshold for initiating active therapeutic or pharmacological interventions [5, 6]. Epidemiology, Etiology, and Clinical Presentation. **Generalized anxiety disorder** has a 1-year prevalence of approximately 1 percent in adolescents and nearly 3 percent in adults source 16. Females are twice as likely as males to develop the condition, with peak onset occurring in late adolescence or early adulthood source 16. Genetic factors account for approximately 30 percent of disease risk, operating alongside dysregulation in **serotonin**, **GABA**, **norepinephrine**, and **glutamate** neurocircuitry source 17. Psychological factors and family modeling also contribute, as patients often describe a family history of severe worry source 18. **Board trap.** Clinicians must remember that 75 percent of patients with **generalized anxiety disorder** seek medical care for physical or somatic complaints such as muscle aches, gastrointestinal distress, or chronic fatigue rather than psychiatric distress source 11. Furthermore, 50 to 90 percent of patients carry a comorbid psychiatric diagnosis, most commonly **major depressive disorder** or substance use disorders, and 25 percent eventually experience **panic disorder** source 12. Because patients often cope for years before seeking treatment, chronic worry can exhaust neural circuits and lead to secondary depression source 19. Treatment Strategy and Psychopharmacology. **First-line** psychotherapy for motivated, psychologically minded patients is **cognitive behavioral therapy** (**CBT**), which holds the strongest empirical support [6, 20]. **First-line** psychopharmacotherapy consists of **SSRIs** such as **sertraline** or **SNRIs** such as **duloxetine** [6, 7]. **Buspirone** is a non-benzodiazepine anxiolytic that carries an official FDA indication for **generalized anxiety disorder** [6, 7]. **Safety alert.** Cautiously consider initiating psychotropic medications on the very first visit [6, 14]. Patients with severe anxiety frequently read medication package inserts thoroughly and may reject treatment if they experience transient initial activation or side effects source 14. Start at a low dose, such as half the standard starting dose, and titrate slowly [6, 21]. When starting an **SSRI**, clinicians may prescribe a short-term **benzodiazepine** bridge for 2 to 3 weeks to manage transient activation [6, 13]. Standard treatment duration is 6 to 12 months, though chronic cases may require long-term maintenance source 13. Patients must be educated that abrupt discontinuation leads to a 25 percent relapse rate in the first month and a 60 to 80 percent relapse rate over the following year [13, 14]. Fitzgerald Sample Board Exam Questions. Practice Question 1. Question: Which of the following is not an essential diagnostic component of GAD? * A. Irritability * B. Restlessness * C. Sleep disturbance * D. Sexual dysfunction Pause. Answer. D. Keyed Answer: D Why It Is Correct: Sexual dysfunction is not a diagnostic criterion component of **generalized anxiety disorder** under the DSM-5-TR **WATCHERS** framework [22, 23]. While sexual dysfunction may occur secondary to chronic anxiety or antidepressant therapy, it is not one of the six core diagnostic criteria [4, 23]. Why the Other Choices Are Wrong: * A. Irritability represents hyperarousal or irritability, which is the H in the **WATCHERS** diagnostic mnemonic [4, 23]. * B. Restlessness represents feeling keyed up or on edge, which is the R in the **WATCHERS** diagnostic mnemonic [4, 23]. * C. Sleep disturbance, particularly difficulty initiating sleep, represents the S in the **WATCHERS** diagnostic mnemonic [4, 23]. Practice Question 2. Question: A 28-year-old female presents for help in managing a generalized anxiety disorder. An appropriate first-line agent is: * A. Sertraline * B. Duloxetine * C. Bupropion * D. Nortriptyline Pause. Answer. A. Keyed Answer: A Why It Is Correct: **Sertraline** is an **SSRI**, which is recognized as a primary **first-line** pharmacological class for treating **generalized anxiety disorder** [24, 25]. **SSRIs** effectively modulate serotonergic tone to reduce chronic worry and autonomic arousal [17, 25]. Why the Other Choices Are Wrong: * A. **Sertraline** is the correct **first-line** choice as an **SSRI** [24, 25]. * B. **Duloxetine** is an **SNRI** that is also effective, but **sertraline** is the keyed **SSRI** selection in this specific review question [24, 25]. * C. **Bupropion** is an NDRI that can exacerbate anxiety or physical agitation and is not a first-line treatment for GAD [24, 25]. * D. **Nortriptyline** is a tricyclic antidepressant associated with higher anticholinergic and cardiovascular risks, making it a secondary or tertiary option [24, 25]. 🧠 Would you like to cover the next leaf in Chapter 9, focusing on Panic Disorder criteria, agoraphobia differentials, and benzodiazepine pharmacokinetics? Next. Topic. GAD Rating Scales (GAD-7). Bottom Line Summary. * **Generalized anxiety disorder** requires excessive anxiety and worry occurring on most days for at least **6 months** regarding multiple events or activities. * Adults must meet at least **3 out of 6** somatic and cognitive symptoms from the **WATCHERS** mnemonic, whereas children require only **1 symptom**. * The **GAD-7** is a 7-item self-report scale where scores of **5 to 9** indicate mild anxiety, **10 to 14** indicate moderate anxiety, and **15 to 21** indicate severe anxiety. * First-line pharmacotherapy for **generalized anxiety disorder** includes **SSRIs** like **sertraline** or **SNRIs** like **duloxetine**, along with **buspirone**, which has a direct FDA indication for GAD. * **Benzodiazepines** should be limited to short-term bridging for **2 to 3 weeks** during initial SSRI titration, and **alprazolam** must be tapered no faster than **0.25 mg per week** to prevent severe withdrawal, seizures, and delirium. * Up to **75 percent** of GAD patients present in primary care or medical specialty clinics with somatic complaints rather than chief complaints of anxiety. * Comorbidity is high, with **50 to 90 percent** of GAD patients having another psychiatric disorder, most commonly **major depressive disorder** or substance use disorders. High-Yield Concept Map: GAD-7 and Diagnostic Criteria. Generalized Anxiety Disorder Rating Scale. * **What it is:** The **GAD-7** is a brief 7-item self-report tool developed by the creators of the PHQ-9 to screen for and monitor generalized anxiety disorder severity. * **Why boards care:** The exam tests your ability to interpret standardized score ranges to determine clinical severity and evaluate treatment response. * **Must know thresholds:** A score of **5 to 9** represents mild anxiety. A score of **10 to 14** represents moderate anxiety. A score of **15 to 21** indicates severe anxiety. Scores of **10 or greater** warrant further diagnostic evaluation and treatment planning. * **First-line:** Administer the **GAD-7** at baseline and follow-up visits to track symptom reduction alongside evidence-based psychotherapy or pharmacotherapy. Diagnostic Criteria and Timelines. * **What it is:** **Generalized anxiety disorder** is a chronic condition defined by uncontrollable, excessive worry across multiple life domains. * **Why boards care:** Test writers expect you to distinguish chronic GAD from acute stress responses, panic disorder, and medical mimics. * **Must know criteria:** Symptoms must persist on most days for at least **6 months**. Adults require **3 or more** WATCHERS criteria: worry difficulty, anxiety, tension in muscles, concentration problems or mind going blank, hyperarousal or irritability, energy loss or fatigue, restlessness, and sleep disturbance. Children require only **1 symptom**. * **First-line:** **Cognitive behavioral therapy** is the first-line psychotherapy with the strongest evidence base. **SSRIs** like **sertraline** and **SNRIs** are first-line psychotropics. * **Safety alert:** Always rule out general medical conditions like hyperthyroidism or pheochromocytoma, as well as substance-induced anxiety, before confirming a primary GAD diagnosis. * **Board trap:** Do not confuse GAD with adjustment disorder with anxious mood. Adjustment disorder symptoms develop within **3 months** of a specific stressor and last no longer than **6 months** after the stressor resolves. GAD requires **6 or more months** of pervasive worry without requiring an acute precipitating stressor. Diagnostic Look-Alikes and Differential Analysis. * **Medical conditions versus GAD:** Hyperthyroidism, pheochromocytoma, cardiac arrhythmias, and chronic obstructive pulmonary disease produce sympathetic hyperarousal that mimics GAD. Medical rule-outs and laboratory baselines are required before initiating psychiatric treatment. * **Substance-induced anxiety versus GAD:** Onset occurs within **1 month** of substance intoxication, withdrawal, or medication ingestion. Common causative agents include stimulants, sympathomimetics, bronchodilators like **theophylline**, antihistamines like **diphenhydramine** in older adults, and antiparkinsonian dopaminergics like **levodopa**. * **Panic disorder versus GAD:** Panic disorder features recurrent, unexpected panic attacks that peak within **10 minutes**, accompanied by persistent worry about future attacks or behavioral changes. GAD involves persistent, pervasive worry lasting at least **6 months** without discrete sudden peaks. * **Adjustment disorder with anxious mood versus GAD:** Adjustment disorder occurs within **3 months** of an identifiable stressor and resolves within **6 months** once the stressor or its consequences terminate. Psychopharmacology and Safety Rules. * **First-line:** **SSRIs** such as **sertraline** and **SNRIs** such as **duloxetine** or **venlafaxine** are primary first-line treatments. **Buspirone** is an effective non-benzodiazepine anxiolytic with an FDA indication for GAD. * **Board trap:** Cautiously consider initiating medications on the very first visit. Patients with GAD are chronic worriers who frequently read drug inserts, over-analyze potential side effects, and may prematurely reject long-acting psychotropics if side effects occur early. * **Short-term bridging:** **Benzodiazepines** may be used for **2 to 3 weeks** to manage transient anxiety spikes when initiating an SSRI, but they must be discontinued promptly. * **Safety alert:** When discontinuing long-term **benzodiazepines** like **alprazolam**, taper no faster than **0.25 mg per week**. Abrupt cessation risks rebound anxiety, severe withdrawal, seizures, delirium, and death. Tapering can also be facilitated by substituting an equivalent dose of a long-acting agent like **diazepam**. Sample Board Practice Questions. Question 1. Which of the following is not an essential diagnostic component of generalized anxiety disorder? A. Irritability B. Restlessness C. Sleep disturbance D. Sexual dysfunction Pause. Answer. D. Why it is correct: Sexual dysfunction is not a diagnostic criterion for generalized anxiety disorder under DSM-5-TR standards. Why the other choices are wrong: * A: Irritability is a core diagnostic criterion included in the WATCHERS mnemonic under hyperarousal. * B: Restlessness or feeling keyed up on edge is a core somatic diagnostic criterion. * C: Sleep disturbance, particularly difficulty initiating sleep, is a core diagnostic criterion. Question 2. A 28-year-old female presents for help in managing generalized anxiety disorder. An appropriate first-line agent is: A. Sertraline B. Duloxetine C. Bupropion D. Nortriptyline Pause. Answer. A. Why it is correct: SSRIs such as sertraline are standard first-line pharmacotherapeutic agents for generalized anxiety disorder. Why the other choices are wrong: * A: Sertraline is the correct first-line choice. * B: Duloxetine is an SNRI that can be used, but sertraline as an SSRI represents a classic first-line board answer. * C: Bupropion lacks efficacy for generalized anxiety disorder and can worsen anxiety symptoms due to its dopaminergic and noradrenergic activity. * D: Nortriptyline is a tricyclic antidepressant and is not a first-line agent due to side-effect profile and safety risks. Question 3. A 32-year-old female with generalized anxiety disorder has been on alprazolam 1 mg three times daily for six months. When considering discontinuation, which of the following statements is false? A. Rebound anxiety symptoms can occur hours to days following discontinuation. B. Withdrawal symptoms are generally considered minimal and non-life-threatening. C. Dosage should be tapered no more than 0.25 mg per week. D. An equivalent dose of diazepam can be substituted prior to tapering doses. Pause. Answer. B. Why it is correct: Statement B is false because benzodiazepine withdrawal is potentially severe and life-threatening, carrying risks of seizures, delirium, and coma similar to alcohol withdrawal. Why the other choices are wrong: * A: Rebound anxiety can indeed emerge hours to days after stopping short-acting benzodiazepines. * B: This statement is false, making it the correct answer to the question stem. * C: Tapering alprazolam at a rate no faster than 0.25 mg per week is a true safety recommendation to avoid withdrawal seizures. * D: Substituting a long-acting benzodiazepine like diazepam is a true and recommended clinical strategy for gradual tapering. Question 4. A 68-year-old man presents with new-onset anxiety symptoms. He provides a list of his current prescription medications. Which of the following is least likely to contribute to his anxiety symptoms? A. Theophylline B. Diphenhydramine C. Methotrexate D. Levodopa Pause. Answer. C. Why it is correct: Methotrexate is an immunosuppressive agent and is least likely to induce psychiatric anxiety symptoms or central nervous system hyperarousal. Why the other choices are wrong: * A: Theophylline is a bronchodilator with stimulant-like properties that frequently causes anxiety and tachycardia. * B: Diphenhydramine can cause paradoxical excitation, restlessness, and anticholinergic toxicity in older adults. * C: Methotrexate is the correct answer because it does not cause medication-induced anxiety. * D: Levodopa is a dopaminergic agent that can induce central nervous system stimulation, psychosis, and severe anxiety symptoms. Question 5. Medical conditions associated with anxiety-like symptoms include all of the following except: A. Chronic obstructive pulmonary disease B. Myocardial infarction C. Hyperglycemia D. Hypoglycemia Pause. Answer. C. Why it is correct: Hyperglycemia does not typically present with acute adrenergic panic or anxiety symptoms. Hypoglycemia, on the other hand, triggers an acute epinephrine surge causing sweating, tremors, tachycardia, and severe anxiety. Why the other choices are wrong: * A: Chronic obstructive pulmonary disease causes hypoxia and hypercapnia, which directly trigger severe physical anxiety. * B: Myocardial infarction frequently presents with an impending sense of doom and acute physical anxiety symptoms. * C: Hyperglycemia is the correct choice because it does not trigger acute sympathetic hyperarousal. * D: Hypoglycemia activates sympathetic surge and is a classic medical mimic of acute anxiety. 💡 **Next Study Step:** Review Panic Disorder and Agoraphobia criteria, focus on high-yield benzodiazepine pharmacokinetics, and contrast unexpected panic attacks with GAD worry patterns. Next. Topic. Panic Disorder Characteristics. Bottom Line Summary. * **Panic disorder** requires recurrent, unexpected **panic attacks** followed by **1 month** or more of persistent worry about future attacks or maladaptive behavioral changes. * A **panic attack** is defined as an abrupt surge of intense fear peaking within **10 minutes**, requiring at least **4 physical symptoms** and **1 psychological symptom**. * **First-line** pharmacotherapy consists of **SSRIs** (such as **sertraline** or **paroxetine**) or **SNRIs** (such as **venlafaxine**); always initiate treatment at **half the usual starting dose** to prevent initial activation. * **Panic disorder** affects women **2 to 3 times** more often than men, with a lifetime prevalence of **1% to 4%** and a mean age of onset of **35 years**. * Comorbidity is high, with **80% to 90%** of patients having at least one other psychiatric condition, most commonly **major depressive disorder** or **agoraphobia**. * Neurobiological etiology involves dysregulation of the noradrenergic system and alterations in **norepinephrine**, **serotonin**, and **GABA** within the **amygdala**, **hippocampus**, and **limbic system**. * **Panic attack** alone is not a mental disorder diagnosis; it serves as a descriptive specifier applicable to any DSM-5-TR psychiatric condition. Panic Disorder Criteria and Diagnostic Features. Clinical Presentation and Diagnostic Criteria. A **panic attack** requires an abrupt surge of intense fear or discomfort reaching a peak within **10 minutes** source 1. The surge requires at least **4 physical symptoms** (such as palpitations, sweating, trembling, shortness of breath, choking feelings, chest pain, nausea, dizziness, paresthesias, chills, or hot flushes) and at least **1 psychological symptom** (intense fear, fear of losing control or going crazy, or fear of dying) [1-3]. Culture-specific symptoms, such as tinnitus, neck soreness, headache, or uncontrollable crying, may occur during an attack but do not count toward the required four DSM-5 symptoms source 4. **Panic disorder** diagnosis mandates recurrent, unexpected **panic attacks** where at least one attack is followed by **1 month** or more of persistent concern about additional attacks, worry about consequences (like having a heart attack), or a significant maladaptive change in behavior to avoid attacks [5, 6]. Safety alert. Always rule out medical mimics (such as hyperthyroidism, pheochromocytoma, cardiac arrhythmias, or myocardial infarction) and substance triggers (such as caffeine, amphetamines, or cocaine intoxication, as well as alcohol or benzodiazepine withdrawal) before establishing a primary psychiatric diagnosis of **panic disorder** [7-9]. Board trap. Do not mistake a **panic attack** for a standalone DSM-5-TR diagnosis source 10. A **panic attack** is an acute event and specifier (for example, PTSD with **panic attacks**) source 10. **Panic disorder** requires recurrent UNEXPECTED attacks and at least **1 month** of anticipatory anxiety or behavioral avoidance [5, 6]. If panic attacks ALWAYS occur after a specific trigger (such as an argument), the attacks are expected, which points away from primary **panic disorder** source 11. First-line Management Strategy. First-line. **SSRIs** (such as **sertraline**, **paroxetine**, or **fluoxetine**) and **SNRIs** (such as **venlafaxine**) are first-line agents for long-term management, paired with **cognitive behavioral therapy** (including interoceptive exposure and relaxation techniques) [12-14]. Board trap. Prescribing standard initial antidepressant starting doses in panic patients often triggers severe initial anxiety or jitteriness (especially with **fluoxetine**), leading patients to abruptly reject daily maintenance therapy source 14. Start at **half the usual starting dose** (for example, **sertraline** 12.5 mg daily) and titrate slowly over several weeks [14, 15]. Short-term bridging with a **benzodiazepine** (such as **clonazepam** or **alprazolam**) for 2 to 3 weeks may be used to control acute surges while an **SSRI** reaches therapeutic efficacy, but long-term dependence must be avoided [16, 17]. Differential Diagnosis and Medical Mimics. Cardiovascular conditions (myocardial infarction, mitral valve prolapse, arrhythmias) and respiratory conditions (COPD, pulmonary embolism) present with chest pain and dyspnea that mimic acute panic source 9. Endocrine and metabolic conditions (hyperthyroidism, hypoglycemia, pheochromocytoma) produce autonomic hyperarousal driven by epinephrine or thyroid surge source 9. Central nervous system active substances (stimulants, sympathomimetics, levodopa, theophylline) or acute withdrawal from central nervous system depressants (alcohol, benzodiazepines) trigger severe panic surges [8, 18]. Sample Board Practice Questions. Question 1. During a panic attack, symptoms tend to peak at approximately how many minutes into the episode? - A. 2 minutes - B. 5 minutes - C. 10 minutes - D. 20 minutes Pause. Answer. C . Why it is correct: Panic attacks are characterized by an abrupt surge of intense fear or discomfort that reaches peak intensity within **10 minutes** source 1. Why the other choices are wrong: - A. 2 minutes is too rapid for the full constellation of autonomic and cognitive symptoms to reach peak surge. - B. 5 minutes precedes the classic ten minute peak threshold defined in diagnostic criteria. - D. 20 minutes exceeds the rapid ten minute peak window characteristic of acute panic attacks. Question 2. Which of the following symptoms is not consistent with a panic attack? - A. Sensation of shortness of breath - B. Chest pain - C. Fear of dying - D. Fatigue Pause. Answer. D . Why it is correct: Fatigue is a chronic vegetative symptom associated with generalized anxiety disorder and major depression, not an acute diagnostic symptom of a panic attack source 19. Why the other choices are wrong: - A. Shortness of breath or smothering sensation is a classic physical symptom of a panic attack source 2. - B. Chest pain or discomfort is a cardinal autonomic symptom of a panic attack source 2. - C. Fear of dying is a primary cognitive psychological symptom during an acute panic surge source 2. Question 3. True or False? The comorbidity rate of panic disorder with other psychiatric disorders is approximately 80 percent, and the rate of panic disorder is two times higher in women compared to men. - A. True - B. False Pause. Answer. A . Why it is correct: Panic disorder carries a high comorbidity rate of 80 to 90 percent with other psychiatric conditions, and affects females 2 to 3 times more frequently than males . Why the other choice is wrong: - B. False is incorrect because both epidemiological parameters reflect established national board exam data. Question 4. The abnormal regulation of all of the following neurotransmitters or hormones is implicated in panic disorder except: - A. Norepinephrine - B. Thyroid stimulating hormone - C. Serotonin - D. Gamma-aminobutyric acid (GABA) Pause. Answer. B . Why it is correct: Thyroid stimulating hormone is an endocrine laboratory marker evaluated to rule out thyroid disease, not a central neurotransmitter whose direct brain pathway dysregulation causes panic disorder . Why the other choices are wrong: - A. Noradrenergic system dysregulation plays a central role in triggering panic attacks . - C. Serotonin system dysfunction is directly involved in panic pathways and targeted by first-line SSRIs . - D. GABA hypoactivity reduces central inhibition, contributing to acute autonomic panic surges . Question 5. Ashley, a 28-year-old female, presents for a psychiatric evaluation stating her doctor thought she might have panic disorder. She has had two panic attacks that caused her to go to the emergency department, where a thorough workup revealed no physical problems. Which of the following statements would not be consistent with a diagnosis of panic disorder? - A. My attacks always happen after I have had a bad argument with my boyfriend. - B. I felt a sense that I was not really present. - C. It came from nowhere, I had to pull the car over because my heart was pounding. - D. I am afraid it might happen again, so I am hesitant to go too far from home. Pause. Answer. A . Why it is correct: Panic disorder requires recurrent unexpected panic attacks that occur out of the blue source 5. Attacks that consistently happen only after a specific situational trigger (such as an argument) represent expected panic attacks linked to interpersonal conflict or another disorder . Why the other choices are wrong: - B. Derealization or depersonalization (feeling unreality or not present) is a classic psychological panic symptom source 3. - C. An attack occurring out of the blue while driving illustrates the unexpected nature required for panic disorder source 5. - D. Anticipatory anxiety about future attacks and resulting behavioral avoidance meet the **1 month** DSM-5-TR criteria for panic disorder source 6. Next. Topic. Social Anxiety and Specific Phobias. Bottom Line Summary. * **Social anxiety disorder** requires marked fear or anxiety lasting **6 months or longer** regarding one or more social or performance situations where the individual is exposed to potential scrutiny, humiliation, or rejection by others. * **Specific phobia** requires marked fear or anxiety lasting **6 months or longer** in response to a circumscribed object or situation, such as animals, natural environments, or blood-injection-injury, which is either actively avoided or endured with intense distress. * Epidemiology reveals an adult 12 month prevalence of **7%** for **social anxiety disorder**, with **75%** of cases demonstrating a peak age of onset between **8 and 15 years** (range **5 to 39 years**). * **Specific phobia** carries a lifetime prevalence of **11%**, featuring a bimodal age of onset that peaks between **5 to 9 years** for animal, storm, and blood-injection phobias, and in the **late 20s** for other situational phobias. * Genetics play a major role in etiology, as first degree relatives of individuals with **social anxiety disorder** are **2 to 6 times more likely** to develop the condition. * **First-line** pharmacotherapy for generalized **social anxiety disorder** consists of **SSRIs** or **SNRIs**. * **First-line** pharmacotherapy for performance-only social anxiety consists of a beta-adrenergic receptor antagonist, specifically **propranolol** (**20 to 40 mg**) or **atenolol** (**50 to 100 mg**), administered **1 hour prior** to the performance or public speaking event. * **First-line** psychotherapy for both conditions is behavioral therapy, utilizing **systematic desensitization** and graded **exposure therapy** from least to most frightening stimuli. Clinical Teaching and Diagnostic Framework. Diagnostic Criteria and Timelines. **Social anxiety disorder** (also known as social phobia) is characterized by an excessive fear of social interactions, being observed, or performing in front of others. The essential diagnostic driver is the patient's intense fear that they will act in a way or show anxiety symptoms that will be humiliating, embarrassing, or lead to rejection. The feared social situations almost always provoke fear or anxiety and are either avoided entirely or endured with severe distress. The fear or anxiety is distinctly out of proportion to the actual threat posed by the social context. To meet **DSM-5-TR** criteria, these symptoms must persist for **6 months or longer** and cause clinically significant impairment in social, occupational, or daily functioning [1-3]. **Specific phobia** criteria closely approximate those of **social anxiety disorder**, with the core substitution of a circumscribed object or situation in place of social scrutiny [3, 4]. Common categories include animals, natural environments, blood-injection-injury, and specific situations source 4. Like social anxiety, exposure to the phobic stimulus produces immediate anxiety, the stimulus is actively avoided or endured with intense dread, the fear is out of proportion to the objective danger, and the duration must be at least **6 months** [2, 3]. Compare and Distinguish: Social Anxiety vs. Specific Phobia. When comparing these two phobic conditions, remember that both share the same **6 month** diagnostic duration requirement and both rely on behavioral avoidance as a primary coping mechanism [2, 3]. Where they differ is in the nature of the core threat and the age of onset patterns [1, 5]. **Social anxiety disorder** centers on interpersonal evaluation and fear of rejection, peaking between **8 and 15 years** of age [1, 5, 6]. In contrast, **specific phobia** centers on non-social objects or physical harm, displaying a bimodal onset that peaks early in childhood between **5 to 9 years** for animal or environmental triggers, and again in the **late 20s** for situational triggers [5, 7]. Etiology and Comorbidities. The etiology of social and specific phobias involves an interplay of neurochemical, genetic, behavioral, and environmental factors [6, 8, 9]. Neurochemically, central and peripheral dysregulation of **norepinephrine** and **epinephrine** release, along with altered adrenergic and dopamine sensitivity, mediates the acute autonomic hyperarousal symptoms such as tachycardia, diaphoresis, and muscle tension [8, 9]. Environmentally, experiences such as childhood bullying, adverse childhood experiences, discrimination, and severe social humiliation increase vulnerability source 8. **Board trap**: Do not confuse **social anxiety disorder** with **generalized anxiety disorder** or **panic disorder**. Patients with **social anxiety disorder** experience autonomic arousal and panic-like symptoms strictly in response to perceived social scrutiny or performance situations [1, 10, 11]. In contrast, **generalized anxiety disorder** involves pervasive, uncontrollable worry across multiple everyday non-social life domains, while **panic disorder** is defined by recurrent, unexpected panic attacks that occur out of the blue without a situational trigger [12-14]. Comorbidities are extremely common in **social anxiety disorder** source 6. Up to two-thirds of individuals have additional psychiatric conditions, most frequently other anxiety disorders, major depressive disorder, or substance-related disorders source 6. Patients frequently attempt to self-medicate their social fear using alcohol or other central nervous system depressants, creating a heightened risk for co-occurring alcohol use disorder [6, 15]. Treatment Standards and Signposts. **First-line** psychotherapeutic management for both **social anxiety disorder** and **specific phobia** is behavioral therapy, particularly **systematic desensitization** and graded **exposure therapy** [9, 16]. Patients are guided through a hierarchy of feared stimuli, from least to most frightening, while practicing relaxation techniques to extinguish the conditioned fear response source 16. **First-line** pharmacotherapy for chronic or generalized **social anxiety disorder** consists of **SSRIs** or **SNRIs** source 16. Medication management requires adequate therapeutic trials at standard antidepressant dosages, often taking several weeks to demonstrate full clinical efficacy [17, 18]. For performance-only social anxiety (such as fear of public speaking, musical performances, or formal presentations), **first-line** intervention is targeted pre-performance dosing with a beta-adrenergic receptor antagonist [15, 16]. Giving **propranolol** at **20 to 40 mg** or **atenolol** at **50 to 100 mg** orally **1 hour prior** to the performance effectively blocks peripheral beta-receptors, suppressing distressing autonomic signs such as tremor, tachycardia, and palpitations without causing sedation source 15. **Safety alert**: Avoid prescribing short-acting **benzodiazepines** as a primary or routine strategy for performance anxiety source 15. While an immediate-acting benzodiazepine can suppress acute panic, long-term or repeated use in performers carries a substantial risk of tolerance, physiological dependence, and secondary substance use disorder source 15. Fitzgerald Sample Test Question. Question 11: Evan is a 26-year-old factory worker. He describes intense anxiety and excessive worry. This occurs any time he is asked to speak to his boss. He has a difficult time approaching his coworkers because he feels very self-conscious. He believes he is missing out on possibly important work information because he cannot join into the group of coworkers. He relates racing heart rate, shallow breathing, and chest tightness. Evan's symptoms are most consistent with: A. Social anxiety disorder B. Generalized anxiety disorder C. Panic disorder with agoraphobia D. Post-traumatic stress disorder Pause. Answer. Keyed Answer: A. Social anxiety disorder Why It Is Correct. Evan's clinical presentation is classic for **social anxiety disorder** [10, 11]. His anxiety, excessive worry, and autonomic symptoms (racing heart, shallow breathing, chest tightness) are specifically triggered by social interactions, such as speaking with a supervisor or approaching peers, driven by fear of being self-conscious or negatively evaluated [10, 19]. Furthermore, his avoidance of group interactions directly causes functional occupational impairment [10, 19]. Why the Other Choices Are Wrong. * A is the correct answer. * B fails because **generalized anxiety disorder** requires pervasive, uncontrollable worry regarding multiple broad life circumstances (such as finances, health, or family) occurring on most days for at least **6 months**, rather than anxiety restricted exclusively to social scrutiny [10, 12]. * C fails because **panic disorder** requires recurrent, unexpected panic attacks that occur spontaneously without a specific situational trigger, accompanied by persistent worry about future attacks or agoraphobic avoidance of places where escape might be difficult [10, 13, 14, 20]. * D fails because **post-traumatic stress disorder** requires direct or indirect exposure to an extreme traumatic event involving actual or threatened death, serious injury, or sexual violence, accompanied by intrusive re-experiencing, trauma-related avoidance, and hyperarousal lasting greater than **1 month** [21-24]. I have delivered the requested study review on **Social Anxiety and Specific Phobias** strictly grounded in your Fitzgerald Chapter 9 sources. Would you like to move on to the next leaf in Chapter 9 (such as **Obsessive Compulsive Disorder**) or practice additional board-style recall items on this topic? Next. End of this drive.